Erasca Inc (ERAS)vsRoyalty Pharma Plc (RPRX)
ERAS
Erasca Inc
$11.97
-9.80%
HEALTHCARE · Cap: $3.72B
RPRX
Royalty Pharma Plc
$55.02
-0.76%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
ERAS
Avoid25
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ERAS.
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Trading at 9.4x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ERAS
The strongest argument for ERAS centers on Debt/Equity.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : ERAS
The primary concerns for ERAS are Price/Book, Revenue Growth, EPS Growth.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
ERAS profiles as a value stock while RPRX is a mature play — different risk/reward profiles.
ERAS carries more volatility with a beta of 0.73 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 25/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Erasca Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Erasca Inc. is a pioneering biopharmaceutical firm dedicated to developing innovative targeted therapies for genetically defined cancers, targeting critical unmet needs in oncology. Utilizing its proprietary drug discovery platform, which integrates advanced genomics and precision medicine, the company aims to develop therapies that specifically address mutations driving cancer progression. With a promising pipeline of clinical-stage candidates focused on disrupting vital tumor growth pathways, Erasca is poised to enhance treatment standards and improve patient outcomes. Its commitment to advancing cancer care is further strengthened by strategic partnerships within the oncology research community, establishing Erasca as a leading force in the biopharmaceutical landscape.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?